CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis

Researchers conducted a meta-analysis to compare the efficacy and safety of CAR T-cell therapy versus bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma. They found that in this disease space, CAR T-cell therapy had improved efficacy versus bispecific antibodies, with higher complete response rates. However, CAR T-cell therapy also had increased instances of grade three or higher adverse events compared with the bispecific antibodies.